William Blair Begins Coverage on Dianthus Therapeutics (NASDAQ:DNTH)

William Blair assumed coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH - Free Report) in a research report report published on Wednesday morning, Marketbeat.com reports. The brokerage issued an outperform rating on the stock. William Blair also issued estimates for Dianthus Therapeutics' FY2025 earnings at ($3.26) EPS, FY2026 earnings at ($3.00) EPS, FY2027 earnings at ($2.99) EPS, FY2028 earnings at ($3.11) EPS and FY2029 earnings at ($3.81) EPS.

DNTH has been the subject of a number of other research reports. Guggenheim reaffirmed a "buy" rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Robert W. Baird lowered their price target on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. Wedbush reaffirmed an "outperform" rating and set a $36.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Dianthus Therapeutics presently has an average rating of "Buy" and an average target price of $53.00.

Dianthus Therapeutics Price Performance

NASDAQ DNTH traded up $0.74 during midday trading on Wednesday, hitting $19.12. 101,602 shares of the company traded hands, compared to its average volume of 264,856. The company has a market cap of $614.74 million, a PE ratio of -6.64 and a beta of 1.38. The company's 50-day simple moving average is $18.85 and its 200-day simple moving average is $20.44. Dianthus Therapeutics has a 52 week low of $13.37 and a 52 week high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, topping analysts' consensus estimates of ($0.86) by $0.04. The firm had revenue of $1.16 million during the quarter, compared to analysts' expectations of $0.81 million. Dianthus Therapeutics had a negative return on equity of 29.26% and a negative net margin of 1,544.23%. On average, research analysts predict that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Octagon Capital Advisors LP raised its stake in shares of Dianthus Therapeutics by 11.0% during the 1st quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company's stock valued at $42,478,000 after buying an additional 231,500 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Dianthus Therapeutics by 4.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock valued at $280,000 after buying an additional 618 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of Dianthus Therapeutics by 5.0% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 189,000 shares of the company's stock valued at $3,428,000 after buying an additional 9,000 shares during the last quarter. ADAR1 Capital Management LLC raised its stake in shares of Dianthus Therapeutics by 3.4% during the 1st quarter. ADAR1 Capital Management LLC now owns 18,285 shares of the company's stock valued at $332,000 after buying an additional 602 shares during the last quarter. Finally, Vestal Point Capital LP raised its stake in shares of Dianthus Therapeutics by 58.1% during the 1st quarter. Vestal Point Capital LP now owns 1,700,069 shares of the company's stock valued at $30,839,000 after buying an additional 625,069 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.